Editas Medicine, Inc. (EDIT) AI Stock Analysis
EDIT AI stock analysis summary
AI ResearchEditas Medicine, Inc. is a clinical-stage genome editing biotechnology company advancing CRISPR-based therapies for genetic ocular disorders, blood diseases, and cancers. As of June 30, 2026, the company held a net cash position of $196.1M despite recurring annual net losses, including -$160.1M in FY2025. Although quarterly revenue surged 232.3% year-over-year in the quarter ended June 30, 2026, the stock has declined 93.8% over the past five years.
- Market cap
- $360.9M
- Revenue (TTM)
- $47.0M
- P/E
- —
- 1Y return
- -40.7% S&P 500 16.8%
- Avg. target
- $6.10 159.6% vs last close
Bull case
- Editas Medicine maintains a strong liquidity cushion with $211.6M in cash and short-term investments against just $15.5M in debt as of June 30, 2026.
- Quarterly revenue grew 232.3% year-over-year in the latest quarter ended June 30, 2026.
- Analyst sentiment includes 9 Strong Buy ratings with a mean price target of $6.10, which sits 159.6% above the October 16, 2026 closing price.
Bear case
- The company burned substantial cash in FY2025, generating negative free cash flow of -$165.8M alongside a net loss of -$160.1M.
- Long-term revenue trends show a 5-year CAGR of -14.9%, with analysts projecting a further revenue drop of 24.6% to $19.5M in the next fiscal year.
- Long-term share performance has been weak, with EDIT shares falling 93.8% over the past 5 years while the S&P 500 climbed 83.0%.
What Editas Medicine does
Editas Medicine, Inc. is a clinical-stage genome editing company based in Cambridge, Massachusetts, developing genomic medicines using its proprietary CRISPR technology platform. Its pipeline includes EDIT-101 in Phase 1/2 clinical trials for Leber Congenital Amaurosis 10, EDIT-102 for Usher Syndrome 2A, and EDIT-301 for sickle cell disease and transfusion-dependent beta-thalassemia. Additionally, Editas Medicine develops gene-edited Natural Killer cell therapies, alpha-beta T cell therapies, and gamma delta T cell therapies for cancer, as well as an early discovery program for neurological diseases. The company collaborates with industry partners, including a research collaboration with Juno Therapeutics, Inc.
Growth and profitability
Editas Medicine generated $40.5M in revenue in FY2025, recovering 25.4% after falling 58.6% to $32.3M in FY2024 and reaching $78.1M in FY2023. Over the five years from FY2020 to FY2025, revenue contracted at a compound annual growth rate of -14.9%. The company has consistently operated at steep losses, posting net income of -$237.1M in FY2024 and -$160.1M in FY2025, with R&D expenses of $90.0M in FY2025. For the trailing twelve months, revenue was $47.0M with an operating margin of -167.3% and an EPS of -$0.68. For the quarter ended June 30, 2026, quarterly revenue grew 232.3% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, Editas Medicine held $211.6M in cash and short-term investments against $15.5M in total debt, yielding net cash of $196.1M. The company maintains a current ratio of 3.19 and a debt-to-equity ratio of 0.15 on shareholders' equity of $105.3M. In FY2025, operating cash flow was -$165.2M and free cash flow was -$165.8M, with capital expenditures of $607,000. Over five years, the company's share count increased by 74.5%.
Valuation and performance
At a closing price of $2.35 on October 16, 2026, Editas Medicine had a market capitalization of $360.9M and an enterprise value of $213.9M. The company trades at a price-to-sales multiple of 7.7x, higher than the 4.1x median of its US-listed Healthcare peers. Its price-to-book ratio is 3.9x and EV-to-revenue stands at 4.6x. The stock has underperformed the broader market, falling 40.7% over the past year and 93.8% over five years, compared to gains of 16.8% and 83.0% for the S&P 500.
What analysts expect
Analyst coverage consists of 9 Strong Buy ratings, 2 Hold ratings, and 2 Sell ratings. The mean price target is $6.10, representing an upside of 159.6% from the last close of $2.35. For the current fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.83 on revenue of $25.8M. For the next fiscal year, 7 analysts project revenue to decline 24.6% to $19.5M with an EPS of -$0.75. Editas beat EPS estimates in 3 of the last 4 quarters, with its next earnings report scheduled for November 9, 2026.
Key risks and what to watch
- Continued negative operating profitability is reflected in a trailing twelve month operating margin of -167.3%.
- Shareholder equity has faced substantial dilution, with the share count increasing 74.5% over a 5-year period.
- The equity experiences high volatility and elevated negative sentiment, carrying a beta of 2.00 and a short interest of 24.2% of float.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this EDIT AI stock analysis
This page is an AI-written research summary of Editas Medicine, Inc. (EDIT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: EDIT income statement, EDIT balance sheet, EDIT key metrics, EDIT analyst forecast, EDIT chart. See the EDIT stock overview for the latest quote and news.
EDIT AI stock analysis FAQ
Does Editas Medicine pay a dividend?
Editas Medicine does not pay a dividend. The company directs its capital toward research and clinical development.
What is Editas Medicine's cash position?
As of June 30, 2026, Editas Medicine had $211.6M in cash and short-term investments and $15.5M in total debt, resulting in net cash of $196.1M.
What do analysts forecast for EDIT stock?
Wall Street analysts have a mean price target of $6.10, representing a 159.6% premium over the October 16, 2026 price of $2.35. The rating consensus includes 9 Strong Buy, 2 Hold, and 2 Sell ratings.
When is Editas Medicine's next earnings date?
The company is scheduled to report its next earnings on November 9, 2026.